Financing led by new investor Bain Capital with participation from new investor Wellington Management and all existing investorsProceeds to ...

The $150 million will also go toward Atsena’s preclinical pipeline and expand the use of the biotech’s spreading AAV.SPR ...

Base editing corrected a mutation that causes macular degeneration, highlighting the potential of gene therapy to treat ...

Researchers identified in a new study that exposure to heavy air pollution, especially particulate matter (PM10), is strongly ...

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the ...

Advancements in medical imaging and computational methodologies have significantly transformed the field of ophthalmology, allowing for unmatched precision ...

Iridocorneal endothelial (ICE) syndrome is a rare, irreversibly blinding ocular disorder with an unknown etiology. Lack of targeted effective drugs, inadequate disease prognosis, and high relapse ...

MeiraGTx's innovative gene therapies for ocular diseases & more are backed by strong clinical data and funding. Click here to find out why MGTX stock is a Buy.

Maharashtra Chief Minister Devendra Fadnavis on Sunday lauded the Rashtriya Swayamsevak Sangh (RSS) workers for their efforts ...

Ocular Therapeutix (NASDAQ:OCUL) is a biotech working on treatments for retinal diseases. Since my June 2024 article on them, the company has focused on its flagship drug candidate called ...